Earkart Ltd

Earkart Limited trading window closed from 1st October, 2026 until 48 hours after the declaration of the financial results of the Company for the half year ended 30th September, 2026.

Subsidiary Incorporation

• Board approved incorporation of a Wholly-Owned Subsidiary named SkillNest Educations Private Limited.
• WOS to be 100% owned by Earkart; 9,999 shares to Earkart, 1 share to nominee.
• Initial paid-up capital INR 1,00,000; 10,000 equity shares of INR 10 each.
• Need ROC approval; incorporation completes upon ROC approval and filings.
• Consideration: cash; Earkart to invest INR 1,00,000 via subscription to shares.
• Promoters have no further interest; WOS will be a subsidiary.

agm details

• AGM held on 15 July 2026; mode: physical with VC attendance.
• Notice issued on 23 June 2026.
• Cut-off date for eligibility: 8 July 2026.
• Voting window: 12 July 2026 09:00 IST to 14 July 2026 17:00 IST.
• Total shareholders on cut-off: 252.
• VC attendance at meeting: promoter 4, public 3.

voting results

• Remote e-voting results submitted; Scrutinizer's report enclosed.

IPO & Listing

• IPO completed and listed on BSE SME on 3 October 2025.
• IPO proceeds totaled ₹44.75 crore; ₹30.63 crore utilized; ₹14.12 crore unutilized in escrow.
• Promoter OFS of 3,34,000 equity shares; promoter IPO expenses advanced then recovered.
• Listing enhances governance framework and market visibility.

Financial Performance

• Total income ₹541.42m, up about 25.3% YoY.
• PAT ₹49.32m, down from ₹66.41m prior year.
• PBT ₹72.56m; profitability pressured by higher logistics and costs.

International Expansion

• US subsidiary Earkart Inc. incorporated Jan 2026; not operational by 31 Mar 2026.
• 100% owned; established to explore international opportunities.
• No revenue from USA subsidiary in FY26.

ESOP & Governance

• ESOP Scheme 2025 approved; Amended 2026; max 8,25,236 options.
• ESOP may extend to eligible employees of subsidiaries.
• Board/NRC to determine eligibility and vesting terms.
• Shares issued on exercise rank pari passu with existing shares.

Capital Structure & IPO Proceeds

• Equity capital post-IPO: 13,753,932 shares (₹137.54m).
• Promoter/promoter group held ~57.34% post-IPO.
• Unutilized IPO proceeds ₹14.12 crore in escrow.

Governance & Internal Controls

• Board meetings: 10 in FY2025-26; MD is Chair.
• Audit Committee met 7 times; independent chair.
• Secretarial Audit flagged UPSI recording in SDD and cost records.
• Form FC filing for USA subsidiary pending; corrective measures underway.

Risks & Outlook

• Opportunities: growing healthcare demand and digital distribution.
• Risks: regulatory changes, licensing, pricing, competition, supply chain, cybersecurity.
• Management focus: expand customer base, cost optimization, tech-enabled distribution.

Employees & CSR

• 58 employees as of 31 Mar 2026.
• CSR spend ₹9,14,633; PM CARES Fund and Smart Class for Diverse Disabilities.
• No sexual harassment complaints; no maternity issues.

AGM & Shareholding

• AGM on 15 July 2026; VC/OAVM; record date 8 July 2026.
• Ordinary business: reappointment of Rahul Salesha; special: ESOP amendments.
• Remote e-voting window: 12–14 July 2026.

AGM Details

• AGM held on 15 July 2026 at 3:00 PM IST via VC/OAVM.
• Record date: 08 June 2026; total shareholders on record: 252.

Key Resolutions

• Ordinary: Adoption of Audited Financial Statements and related reports.
• Ordinary: Re-appointment of Mr. Rahul Salesha as Director.
• Special: Ratification and approval of Amended and Restated ESOP Scheme 2025- Amended 2026.

Voting Status

• Voting results to be submitted later; final results not disclosed in filing.

Other Governance

• ESOP amendment subject to shareholder approval; no other changes disclosed.

Dematerialisation/rematerialisation status

• Certificate under Reg 74(5) for the quarter end date received from the RTA.

AGM Notice Details

• AGM: 5th AGM scheduled for 15 July 2026 at 3:00 PM IST via VC/OAVM.
• Newspaper notices published 25 June 2026 in Financial Express (English) and Jansatta (Hindi).
• Notice also published on the company's website.
• Notice issued under SEBI LODR Reg 30 and MCA/SEBI circulars.
• Corporate name updated to Earkart Limited from Earkart Private Limited.
• Company Secretary & Compliance Officer: Preeti Srivastava (Membership No. A31615).

Earkart Pharmaceuticals

• Proposed wholly owned subsidiary of Earkart Limited.
• Pharmaceuticals sector; intended to manufacture, promote, sell, and distribute products.
• Proposed authorised and paid-up share capital: Rs. 1,00,000 each.
• Turnover not applicable; entity is yet to be incorporated.
• Related party once incorporated; promoters and group companies have no other interest.
• Acquisition is 100% subscription to initial share capital in cash.
• Shares to be subscribed at face value of Rs. 10 each.
• No regulatory approvals or completion timeline specified.

Earkart Healthcare Services

• Proposed wholly owned subsidiary of Earkart Limited.
• Healthcare sector; intended to provide healthcare services.
• Proposed authorised and paid-up share capital: Rs. 1,00,000 each.
• Turnover not applicable; entity is yet to be incorporated.
• Related party once incorporated; promoters and group companies have no other interest.
• Acquisition is 100% subscription to initial share capital in cash.
• Shares to be subscribed at face value of Rs. 10 each.
• No regulatory approvals or completion timeline specified.

Board outcome

• 📍 Board approved audited standalone results for half year and year ended 31 March 2026.
• 📍 Board appointed internal auditor and secretarial auditor for FY 2026-27.

Audit opinion

• 📊 Statutory auditors issued an unmodified opinion on the standalone financial results.
• 📊 Results were prepared under Accounting Standards and Regulation 33 of SEBI Listing Regulations.

Accounting notes

• 📊 Half-year figures to 31 March 2026 are balancing figures between audited annual and prior unaudited numbers.
• 📊 Company operates in one primary segment: manufacture and distribution of modern hearing aids and accessories.
• 📊 EPS was computed under AS-20 and not annualised for the half year.
• 📊 No exceptional or extraordinary items were reported for the period.

Auditor appointments

• 📍 M/s Arvind Aggarwal & Associates was appointed internal auditor for FY 2026-27.
• 📍 M/s Nikita Kothari & Associates was appointed secretarial auditor for FY 2026-27.

Business

• Earkart manufactures and distributes modern hearing aids and related accessories.